stockportfolio.pro
Stocks / KRYS vs PODD
KRYS vs PODD
Krystal Biotech, Inc. and Insulet Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
PODD is the larger company ($9.9B vs $9.2B). On the fundamentals, KRYS earns a higher net margin (52.6% vs 9.1%); KRYS has the stronger return on equity (16.8% vs 16.3%); PODD trades cheaper on earnings (33.5× vs 42.0×). Full numbers below — the stronger figure on each row is in green.
| Krystal Biotech, Inc. (KRYS) | Insulet Corporation (PODD) | |
|---|---|---|
| Market cap | $9.2B | $9.9B |
| Revenue (latest FY) | $389.13M | $2.71B |
| Net income (latest FY) | $204.83M | $247.10M |
| Revenue growth (5y CAGR) | — | 24.5% |
| Net margin | 52.6% | 9.1% |
| Return on equity | 16.8% | 16.3% |
| P/E ratio | 42.0 | 33.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 8 |
| Positive free cash flow | Yes | Yes |
Compare with another company:
See the full KRYS vs PODD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open KRYS's full financials → Open PODD's full financials →More comparisons
Frequently asked questions
Which is bigger, KRYS or PODD?
Insulet Corporation is larger by market capitalization — $9.9B versus $9.2B.
Which grows faster, KRYS or PODD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.